Abstract| Volume 18, ISSUE 6, SUPPLEMENT , S11-S12, June 2016

Extended Product Release Testing in Stem Cell Transplantation and Cellular Immunotherapy of Patients with Multiple Myeloma. Development of Highly Standardized and Sensitive Detection of Malignant Plasma Cells in Autologous Cell Products and Peripheral Blood of Myeloma Patients by Flow Cytometry

      Introduction: Detection and enumeration of malignant plasma cells at the time of stem cell collection prior to autologous stem cell transplantation identifies patients with high risk of progression. There is a rising demand for introduction of highly standardized, rapid and sensitive assays for minimal residual disease (MRD) testing to improve quality control of cellular products and patient monitoring.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect